McKenna W G, Weiss M C, Endlich B, Ling C C, Bakanauskas V J, Kelsten M L, Muschel R J
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104.
Cancer Res. 1990 Jan 1;50(1):97-102.
Resistance of tumors to irradiation or chemotherapeutic agents is thought to be one of the reasons why patients who present with early malignancies may not be cured. Much is now known about the molecular mechanisms that underlie drug resistance, but until recently little was known about genetic contributions to radiation resistance. Some evidence now links oncogenes, particularly the ras family of oncogenes, to radiation resistance but heterogeneity between tumors and cell lines has complicated this analysis. Primary rat embryo cells have been chosen as a model system in which the effects on radiation resistance of the H-ras oncogene could be studied on a uniform genetic background. These cells offer several useful advantages. The cells prior to transformation are diploid, and because they have been in culture only for a few passages prior to transformation with the oncogene it is unlikely that any preexisting mutation affecting radiation response could be present. Additionally, the use of rat embryo cells permitted the study of the effects of a second oncogene on the appearance of the radioresistant phenotype. The results show that the activated H-ras oncogene is associated with radiation resistance in primary rat cells after transformation but that the effect of the oncogene by itself is small. However, the oncogene v-myc, which has no effect on radiation resistance by itself, has a synergistic effect on radiation resistance with H-ras. There appear to be differences in the phenotype of radiation resistance associated with these two forms of transfectants. Thus, radiation resistance seen with H-ras by itself is characterized by a change in the slope of the radiation survival curve at high radiation doses but little or no change within the should region of the radiation survival curve. Radiation resistance seen in H-ras plus v-myc transformants is also characterized by an increase in the slope of the curve at high doses but there is also a large effect within the shoulder region of the radiation survival curve. These studies led to the following conclusions: (a) the radioresistant phenotype is not due to preexisting genetic heterogeneity in the cells prior to transfection; (b) the radiation resistant phenotype of cells transformed by H-ras is seen to a greater degree in cells which also contain the v-myc oncogene; (c) the v-myc oncogene may play an important role in the phenotype of radiation resistance at low doses that is within the range most critical for clinical practice.
肿瘤对放疗或化疗药物的耐药性被认为是早期恶性肿瘤患者无法治愈的原因之一。目前,我们对耐药性背后的分子机制已经有了很多了解,但直到最近,对于遗传因素对辐射抗性的影响仍知之甚少。现在有一些证据将癌基因,特别是癌基因的ras家族,与辐射抗性联系起来,但肿瘤和细胞系之间的异质性使这一分析变得复杂。原代大鼠胚胎细胞已被选为一个模型系统,在这个系统中,可以在统一的遗传背景下研究H-ras癌基因对辐射抗性的影响。这些细胞具有几个有用的优点。转化前的细胞是二倍体,而且由于它们在用癌基因转化前只培养了几代,所以不太可能存在任何影响辐射反应的预先存在的突变。此外,使用大鼠胚胎细胞可以研究第二个癌基因对辐射抗性表型出现的影响。结果表明,活化的H-ras癌基因在转化后的原代大鼠细胞中与辐射抗性相关,但癌基因本身的作用很小。然而,癌基因v-myc本身对辐射抗性没有影响,但与H-ras对辐射抗性有协同作用。与这两种转染形式相关的辐射抗性表型似乎存在差异。因此,单独的H-ras所导致的辐射抗性表现为在高辐射剂量下辐射存活曲线斜率的变化,但在辐射存活曲线的肩部区域几乎没有变化或没有变化。在H-ras加v-myc转化体中看到的辐射抗性同样表现为在高剂量下曲线斜率的增加,但在辐射存活曲线的肩部区域也有很大影响。这些研究得出了以下结论:(a) 辐射抗性表型不是由于转染前细胞中预先存在的遗传异质性;(b) 在同时含有v-myc癌基因的细胞中,H-ras转化细胞的辐射抗性表型更为明显;(c) v-myc癌基因可能在低剂量辐射抗性表型中起重要作用,而低剂量范围对临床实践最为关键。